Wednesday, September 2, 2026

2:15 PM - 3:45 PM

---

Details

Organised by the FIP Ethics Advisory Group in collaboration with the FIP Regulatory Advisory Group and the FIP Social and Administrative Pharmacy Section Chair(s) Dr Maria Allinson, Member, the FIP Ethics Advisory Group, UK & Ass. Prof. Betty Chaar, Executive Committee Member, the FIP Ethics Advisory Group, Australia Introduction: The integration of Artificial Intelligence (AI) technologies has the potential to transform the delivery of healthcare systems. AI is being used to analyse big data to inform and streamline processes, including aiding automation of repetitive and predictable processes (e.g., clinical decision support, personalised medicine services, detection and prediction of medical errors and adverse drug reactions). Pharmacists have a pivotal role in ensuring safe and efficient medicines management within healthcare systems. With the increased complexity of both systems and medicines management, there is an increased demand for automation and AI tools to enhance and optimise pharmacy practice. How do we ensure transparency, equity, and respect for patient autonomy when AI informs care decisions? With every innovation or new service provision in pharmacy, there are new responsibilities and ethical issues that need to be articulated and clarified. For example, the use of AI tools presents challenges with patient data security and potential for perpetuating bias. The use of AI transcends geographical global boundaries and requires a global response to ensure we curb and address the negatives, while not stifling innovation and maximising benefits. This session will explore the ethical and regulatory issues that the use of AI in pharmacy practice presents. Programme: Learning objectives: 1. Discussion of emerging global regulatory approaches to AI in pharmacy practice. 2. Explain key ethical principles that inform the responsible use of AI in pharmacy, highlighting how AI also influences population level medication safety and public health decision-making. 3. Examining equity impacts, including data bias and differential access to AI tools. 4. Considering how ethical AI adoption can support workforce capacity, service sustainability, and patient trust. 5. Utilise practical decision-making heuristics for the safe and ethical use of AI in clinical and practice settings. 6. Discuss examples of how pharmacists can identify, manage, and escalate AI related ethical or legal concerns. 7. Draft principles that could contribute to emerging professional standards for ethically aligned AI in pharmacy practice. Take home messages: The potential for AI is significant, as is mitigating the unintended harms from AI technologies. Discussing emerging ethical issues and regulatory approaches facilitates global collaboration and congruence in ensuring the safe and responsible use of AI in pharmacy practice. FIP Development Goals: To learn more about these FIP Development Goals, click on the links below. FIP Development Goal 10: Equity and Equality FIP Development Goal 15: People-Centred Care FIP Development Goal 20: Digital Health

---

Chairs & speakers